Teva sues Cipla over generic asthma inhalers
Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
Novavax partners with Takeda to deliver COVID-19 vaccine in Japan
US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.
Teva wins appeal over thyroid drug at Fed Circuit
In a victory for Teva Pharmaceuticals, the US Court of Appeals for the Federal Circuit dismissed IBSA Institut Biochimique’s appeal against a ruling that held parts of its patent invalid.
BMS, Pfizer secure victory over generic makers
In a victory for Bristol-Myers Squibb and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis.
Webinar: antibody patents in Europe and beyond
Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application.
LSPN Connect: micro-managing with Pendulum Therapeutics
With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored.
Federal Circuit won’t revisit revived Illumina DNA test patents
The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
KIPA hires former Decode Genetics director
IP boutique KIPA has strengthened its team with the addition of Iceland-based patent attorney Thorlakur Jonsson.
Medit scores win in 3Shape patent battle
South Korean medical devices manufacturer Medit has prevailed in a patent infringement lawsuit brought by Danish rival 3Shape in Germany.
Fed Circuit orders new Bio-Rad trial, but upholds $24m award
The US Court of Appeals for the Federal Circuit has partially lifted an injunction on 10X Genomics, but the biotech company must still pay almost $24 million for infringing a Bio-Rad patent.
